Proactiveinvestors recommends
Additional Information
Market: LON
Sector: Pharmaceuticals
EPIC: AMP
Amphion Innovations
www.amphionplc.com

Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.

Amphion has a significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

Full Amphion Innovations profile here
Pdf

Amphion Innovations is significantly undervalued against its NAV, says broker

19th Dec 2011, 10:51 am by Giles Gwinnett

Technology commercialisation firm Amphion Innovations (LON:AMP) is significantly undervalued against its net asset value, says Seymour Pierce analyst Dr Mike Mitchell.

The broker has begun coverage on the firm, which focuses on the medical and technology sectors, initiating with a 'buy' targeting a price of 10 pence (current price: 4 pence a share).

"In light of the near-term progress being made across the business, we believe Amphion is significantly undervalued against its NAV," said Mitchell.

However, the analyst conceded that in the light of wider market conditions, that discount was justified.

But he added: "However, with the DataTern business effectively acting as an ‘engine’ for the portfolio business of Amphion, we believe the current approximate 70 per cent discount is overdone.

"Instead, we believe a discount of around 30 per cent is more justified," he said, adding that the broker's own target price had been worked out at 10 pence.

Since floating in 2005, the firm's strategy has been to build high-potential companies with innovative, proprietary, and proven technology.

This approach has delivered a portfolio of partner firms which operate across industrial sectors, and it has a wholly-owned licensing firm called DataTern.

"While capital markets have been restrained in their desire to fund small, emerging tech businesses, Amphion has focused DataTern to deliver what is now a growing stream of IP licensing revenues," said Dr Mitchell.

The analyst added that DataTern's ownership of ObjectSpark patents represented widely-used relational databases, which DataTern had successfully licensed to multinational companies.

"Claims of noninfringement and patent invalidity from Microsoft, SAP AG and SAP America, Inc. have been refuted by Amphion, who continues to enforce these patents against other infringers.

"We anticipate that licensing streams will continue to be an important and growing source of revenue for Amphion in the near-term," concluded the analyst.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.